Cardiotonic Agents Market Report 2026

Cardiotonic Agents Market Overview

• Cardiotonic Agents market size has reached to $3.11 billion in 2025 • Expected to grow to $5.56 billion in 2030 at a compound annual growth rate (CAGR) of 12.3% • Growth Driver: Rise In Cardiovascular Diseases Driving The Growth Of The Market Due To Increasing Prevalence And Demand For Heart-Related Treatments • Market Trend: Short-Term Inotropic Drugs Improve Outcomes In Cardiogenic Shock • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Cardiotonic Agents Market?

Cardiotonic agents are a class of drugs that improve the efficiency and contraction of the heart muscle, improving its ability to pump blood. These agents are used to treat heart failure and certain arrhythmias by increasing cardiac output and improving circulation. The main drug types of cardiotonic agents are digitalis glycosides, phosphodiesterase inhibitors, cardioprotectants, sympathomimetic agents, and others. Digitalis glycosides are compounds derived from the Digitalis plant that are used to treat heart conditions by increasing the force of heart contractions and regulating heart rhythm. They can be administered via oral, intravenous, or other routes, with dosage forms typically including tablets, solutions, and others. These agents are applied in various medical situations, such as cardiac surgeries, atrial fibrillation, heart failure, pulmonary hypertension, and others, and are distributed through hospital pharmacies, retail pharmacies, and online pharmacies.

What Is The Cardiotonic Agents Market Growth Forecast?

The cardiotonic agents market size is expected to see rapid growth in the next few years. It will grow to $5.56 billion in 2030 at a compound annual growth rate (CAGR) of 12.3%. The growth in the forecast period can be attributed to aging global population, increasing advanced heart failure cases, demand for rapid-acting cardiac drugs, expansion of critical care infrastructure, improved monitoring in cardiac intensive care. Major trends in the forecast period include continued use of cardiotonic drugs in acute heart failure, preference for hospital-based intravenous administration, ongoing demand for digitalis glycosides in arrhythmia, integration of cardiotonic agents in surgical cardiac care, gradual shift toward combination cardiovascular therapy.

Global Cardiotonic Agents Market Segmentation

1) By Drug Type: Digitalis Glycosides, Phosphodiesterase Inhibitors, Cardioprotectants, Sympathomimetic Agents, Other Drug Types 2) By Route Of Administration: Oral, Intravenous, Other Route Of Administrations 3) By Dosage Form: Tablet, Solution, Other Dosage Forms 4) By Application: Cardiac Surgical Procedures, Atrial Fibrillation, Heart Failure, Pulmonary Hypertension, Other Applications 5) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies Subsegments: 1) By Digitalis Glycoside: Digoxin, Digitoxin, Lanatoside C 2) By Phosphodiesterase Inhibitors: Milrinone, Enoximone, Amrinone 3) By Cardioprotectants: Coenzyme Q10, Dexrazoxane, Trimetazidine 4) By Sympathomimetic Agents: Dobutamine, Dopamine, Norepinephrine 5) By Other Drug Types: Levosimendan, Omecamtiv Mecarbil, Cilostazol

What Is The Driver Of The Cardiotonic Agents Market?

The rise in prevalence of cardiovascular diseases is expected to propel the growth of the cardiotonic agents market going forward. Cardiovascular diseases (CVDs) refer to a group of disorders that affect the heart and blood vessels, including conditions such as coronary artery disease, heart failure, arrhythmias, and stroke. The rise in cardiovascular diseases is primarily due to unhealthy diets high in saturated fats, trans fats, salt, and added sugars, which contribute to obesity, high blood pressure, and elevated cholesterol levels. Cardiotonic agents improve the efficiency and contraction strength of the heart muscle, thereby supporting better blood circulation and reducing symptoms in various cardiovascular diseases. For instance, in September 2023, according to the World Health Organization, a Switzerland-based intergovernmental organization, there were 17.9 million deaths from cardiovascular diseases.Therefore, the rise in prevalence of cardiovascular diseases is driving the growth of the cardiotonic agents industry.

Key Players In The Global Cardiotonic Agents Market

Major companies operating in the cardiotonic agents market are Pfizer Inc., F. Hoffmann-La Roche AG, Merck & Co. Inc., Bayer AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca plc, Novartis AG, Eli Lilly and Company, Fresenius Kabi, Aurobindo Pharma Limited, Hikma Pharmaceuticals PLC, Alchem International Private Ltd, Farbe Firma Private Limited, Salius Pharma Pvt. Ltd., Johnlee Pharmaceuticals Pvt. Ltd., Healthy Life Pharma Pvt Ltd, Anwita Drugs, Varion Lifesciences, Deccan Nutraceuticals Pvt. Ltd.

Global Cardiotonic Agents Market Trends and Insights

Major companies operating in the cardiotonic agents market are focusing on developing innovative products, such as short-term inotropic drugs, to enhance cardiac performance in acute heart failure and cardiogenic shock. Short-term inotropic drugs are medications used to temporarily enhance the heart's ability to contract, thereby improving cardiac output. For instance, in June 2023, Hikma Pharmaceuticals plc, a UK-based pharmaceutical company, launched Dobutamine Injection, USP, in a 250 mg/20 mL vial. This injection is used for short-term inotropic support in adults experiencing cardiac decompensation due to reduced heart contractility, commonly caused by heart disease or following cardiac surgery. It works by stimulating beta-1 receptors, which enhances heart muscle contractility and cardiac output with a rapid onset (1–2 minutes). The injection is administered intravenously and is typically given in a hospital setting with close monitoring.

What Are Latest Mergers And Acquisitions In The Cardiotonic Agents Market?

In April 2023, SK Capital Partners LP, a US-based capital market company, acquired Apotex Pharmaceutical Holdings Inc. for an undisclosed amount. With this acquisition, SK Capital aims to accelerate Apotex’s growth and innovation by leveraging its expertise to expand global access to affordable, high-quality pharmaceuticals. Apotex Pharmaceutical Holdings Inc. is a Canada-based pharmaceutical company that manufactures a cardiotonic agent under the brand name Apo-Digoxin.

Regional Insights

North America was the largest region in the cardiotonic agents market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Cardiotonic Agents Market?

The cardiotonic agents market consists of sales of digoxin, milrinone, dobutamine, levosimendan, and amrinone. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Cardiotonic Agents Market Report 2026?

The cardiotonic agents market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the cardiotonic agents industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.